XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Share capital
6 Months Ended
May 31, 2021
Share capital  
Share capital

7)    Share capital

Authorized:

unlimited common shares, no par value

in thousands of dollars, except share amounts

Number of shares

Ascribed value

    

  

  

$

  

November 30, 2019

 

140,427,761

177,971

Exercise of options

 

3,297,588

1,133

Restricted Share Units

 

412,501

642

November 30, 2020

 

144,137,850

179,746

Exercise of options

308,635

642

May 31, 2021, issued and outstanding

144,446,485

180,388

(a)

Stock options

During the six-month period ended May 31, 2021, the Company granted 3,374,150 options (2020 - 2,325,000 options) at a weighted-average exercise price of CAD$2.52 (2020 - CAD$2.93) to employees, consultants and directors exercisable for a period of five years with various vesting terms from immediate vesting to vesting over a two-year period. The weighted-average fair value attributable to options granted in the period was $0.84 (2020 - $0.96).

For the six-month period ended May 31, 2021, Trilogy recognized a stock-based compensation charge of $2.60 million (2020 – $1.58 million) for options granted to directors, employees and service providers, net of estimated forfeitures.

The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model.

Assumptions used in the pricing model for the six-month period ended May 31, 2021 are as provided below.

    

May 31, 2021

Risk-free interest rates

 

0.31%

Exercise price

 

1.98

Expected life

 

3 years

Expected volatility

 

64.4%

Expected dividends

 

Nil

As of May 31, 2021, there were 3,176,337 non-vested options outstanding with a weighted average exercise price of CAD$2.63; the non-vested stock option expense not yet recognized was $1.17 million. This expense is expected to be recognized over the next two years.

A summary of the Company’s stock option plan and changes during the six-month period ended May 31, 2021 is as follows:

May 31, 2021

Weighted average

exercise price

    

Number of options

  

  

$

  

Balance – beginning of the year

 

8,647,500

1.84

Granted

 

3,374,150

2.09

Exercised

 

(767,000)

1.67

Cancelled

 

(131,334)

2.52

Balance – end of the period

 

11,123,316

2.03

The following table summarizes information about the stock options outstanding at May 31, 2021.

Outstanding

Exercisable

Unvested

 

Weighted

Weighted

 

Number of

Weighted

average

Number of

average

Number of

 

outstanding

average years

exercise price

exercisable

exercise price

unvested

Range of exercise price

    

options

  

  

to expiry

  

  

$

  

  

options

  

  

$

  

  

options  

  

$0.58 to $1.00

 

1,440,000

 

1.09

0.73

1,440,000

0.73

$1.01 to $1.50

 

75,000

 

1.56

1.22

75,000

1.22

$1.50 to $2.00

 

865,000

 

3.48

1.96

865,000

1.96

$2.01 to $2.50

 

8,705,816

 

3.87

2.25

5,529,479

2.29

3,176,337

$2.51 to $3.00

37,500

2.97

2.82

37,500

2.82

11,123,316

3.46

2.03

7,946,979

1.97

3,176,337

The aggregate intrinsic value of vested share options (the market value less the exercise price) at May 31, 2021 was $6.8 million (2020 - $8.3 million) and the aggregate intrinsic value of exercised options for the six months ended May 31, 2021 was $0.71 million (2020 - $0.18 million).

(b)

Restricted Share Units and Deferred Share Units

The Company has a Restricted Share Unit Plan (“RSU Plan”) and a Non-Executive Director Deferred Share Unit Plan (“DSU Plan”) to provide long-term incentives to employees, officers and directors.  Awards under the RSU Plan and DSU Plan may be settled in cash and/or common shares of the Company at the Company’s election with each restricted share unit

(“RSU”) and deferred share unit (“DSU”) entitling the holder to receive one common share of the Company or equivalent value.  All units are accounted for as equity-settled awards.

A summary of the Company’s unit plans and changes during the six-month period ended May 31, 2021 is as follows:

  

Number of DSUs

   

Balance – beginning of the year

 

1,218,520

Granted

 

35,406

Balance – end of the period

 

1,253,926

For the six-month period ended May 31, 2021, Trilogy recognized a stock-based compensation charge of $0.07 million (2020- $0.39 million), net of estimated forfeitures.  The Company did not issue any RSU grants during the six-month period ended May 31, 2021. As of May 31, 2021, there were no outstanding RSU grants.